CA2311128C - Composition with azelaic acid - Google Patents

Composition with azelaic acid Download PDF

Info

Publication number
CA2311128C
CA2311128C CA002311128A CA2311128A CA2311128C CA 2311128 C CA2311128 C CA 2311128C CA 002311128 A CA002311128 A CA 002311128A CA 2311128 A CA2311128 A CA 2311128A CA 2311128 C CA2311128 C CA 2311128C
Authority
CA
Canada
Prior art keywords
concentration
composition
weight
composition according
azelaic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002311128A
Other languages
French (fr)
Other versions
CA2311128A1 (en
Inventor
Patrick Franke
Clemens Gunther
Jutta Riedl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intendis GmbH
Original Assignee
Intendis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2311128(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intendis GmbH filed Critical Intendis GmbH
Publication of CA2311128A1 publication Critical patent/CA2311128A1/en
Application granted granted Critical
Publication of CA2311128C publication Critical patent/CA2311128C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention relates to a pharmaceutical composition that has the following components: azelaic acid, polyacrylic acid, triacylglycerides, propylene glycol, polysorbates, soybean lecithin, water and salts. The composition is a hydrogel, which is suitable for treatment of rosacea, presbyderma, melasma or skin irritations.

Description

The invention relates to a composition with azelaic acid in a hydrogel. In addition, the use of azelaic acid-hydrogel as a pharmaceutical agent is part of the invention.

Prior Art EP 0 336 880 A2,, which was applied for on 3/29/1998, describes a pharmaceutical composition that consists of (i) azelaic acid at a concentration of 20% by weight, (iii) triacylglycerides and diacylglycerides, (iv) propylene glycol, (v) polysorbate, for example polyethylene (20) sorbitan monooleate, and (vii) water and salts. This composition that is to be administered topically is used for the treatment of various age-related changes in the facial skin. The composition exists as a cream. In addition, it is known to use the azelaic acid for inflammatory and infectious dermatoses, such as, for example, acne and rosacea.

Under the number 32 282, the 1996 Red List (ISBN 3-87193-167-5) describes a pharmaceutical composition with the name Skinoren that consists of (i) azelaic acid at a copcentration of 20% by weight, (iii) triacylglycerides and diacylglycerides, (iv) propylene glycol, (v) polysorbate, for example macrogol stearate 1000 and (Vii) water and salts. This composition that is to be administered topically is used for the treatment of acne. The composition exists as a cream. -International Application WO 96/11700, which was filed on October 29, 1993, describes a pharmaceutical composition that is used as an adjuvant.for a vaccine. This composition is to replace the Freund adjuvant. It is injected. As a (i) pharmaceutical active ingredient, for example, hepatitis B
surface protein is used. In addition, (ii) polyacrylic acid, (iii) triacylglycerides and/or diacylglycerides, such as MIGLYOL, (iv) propylene glycol, and (v) polysorbates are used in the form of TWEEN, EMULROR and SIMULSOL M-53. (vi) Soybean lecithin is also to be added. The composition is an (vii) aqueous phase with salts. The composition is not administered topically. The emulsion has particles measuring 0.03 to 0.5 m, preferably 0.05 to 0.2 Ecm.

International application WO 95/05163, which was filed on August 5, 1994, describes a pharmaceutical composition that exists as an emulsion for the administration of biologically active substances on the skin surface. This composition contains particles measuring 30 to 500 nm, preferably 70 to 200 nm. As (i) pharmaceutical active ingredients, for example, anti-inflammatory medications are used. in addition, (ii) polyacrylic acid, (iii) triacylglycerides and/or diacylglycerides, (iv) .propylene glycol, and (v) polysorbates are used in the form of TWEEN, EMULROR, TRITON X and SIMULSOL M-53. (iv) Soybean lecithin is also to be added. The composition is an (vii) aqueous phase with salts. The composition is administered topically.

European Patent Application EP 0 696 452, which was filed on July 26, 1995, describes a nanoemulsion that is used for medication for-treating the eyes, whereby the nanoemulsion is administered as eye drops that are to be applied topically. This composition contains particles of a mean size of 520 nm. As (i) pharmaceutical active ingredients, for example, anti-inflammatory medications are used. In addition, (ii) polyacrylic acid, (iii) triacylglycerides and/or diacylglycerides, (iv) propylene glycol, and (v) polysorbates are used in the form of polyoxyethylene polyoxypropylene copolymers. The composition is an (vii) aqueous phase with salts. The composition is administered topically.

Object and Achievement An object is to offer a pharmaceutical composition with azelaic acid as a therapeutic active ingredient; whereby the bioavailability of the azelaic acid is increased.

In a composition according to the prior art that comprises the following features:

(i) azelaic acid as a therapeutic active ingredient, (iii) triacylglycerides, (iv) propylene glycol, and (v) polysorbates (vii) in an,aqueous phase that comprises water and salts, the object is achieved in that the composition comprises (ii).polyacrylic acid, and (vi) lecithin, such as soybean lecithin as other additives, and .that in this case the composition is a hydrogel.
Advantages The composition according to the invention has the advantage that it allows a larger amount of pharmaceutical active ingredient to penetrate into living skin layers and/or cutaneous organs. In this connection, the availability of the azelaic acid in the composition according to the invention is higher by a factor of three to five than in the azelaic acid-cream according to the prior art. This availability was demonstrated in -a flow-diffusion cell test according to Franz, described in detail in the examples. Specifically the living skin layers and/or cutaneous organs are the desired target sites for azelaic acid. It is especially common to use the composition in azelaic acid at high concentrations.

Another Embodiment of the Composition A coinposition that is to be administered topically is advantageous.

Preferred is a composition according to the invention in which the azelaic acid is present at a concentration of 5 to 20%

by weight, more preferably at a concentration of 10 to 18%.by weight, and most preferably at a concentration of 14 to 16% by weight.

The presence of polyacrylic acid is essential. It is decisive for the production of the hydrogel. In the gel, the soybean lecithin is preferred as lecithin. The lecithin or soybean lecithin is advantageous at a concentration of up to 3% by weight. More preferred is a concentration of up to 1.5%
by weight and most preferred a concentration of up to 1% by weight. The last concentration has the effect that the hydrogel is no longer present as a nanoemulsion.

Advantages It has unexpectedly proven that the composition according to the invention in the case of concentrations in lecithin of 1$ by weight and less does not form any standard nanoemulsion according to the prior art. Rather, a gel is present that comprises a homogenous mass with virtually no vesicles, but does have membrane fragments. The fact that azelaic acid and the remainder of the solution do not form any nanoemulsion was not expected.
Only with the aid of scanning electron microscope recordings was it possible to provide clarity. It turned out that no nanoemulsion could be identified in microscopic examination.
Advantageously, the composition according to the invention has a high penetration in living skin layers and/or cutaneous organs, which cannot be observed in creams.

Preferred Embodiments Preferred is a composition in which the individual parameters, independently of one another, can have the following concentrations:

(ii) Polyacrylic acid at a concentration of 0.5 to 2%
by weight, (iii) triacylglycerides at a concentration of 0.5 to 5%
by weight, (iv) propylene glycol at a concentration of 5 to 15% by weight, and (v) polysorbates at a concentration of 0.5 to 3% by weight.

The components are to be adapted to one another, of course, so that a sum of 100% is achieved.

Most preferred is a composition in which the individual parameters, independently of one another, can have the following concentrations:

(ii) Polyacrylic acid at a concentration of 1 0.25%
by weight, (iii) triacylglycerides at a concentration of 2 1% by weight, (iv) propylene glycol at a concentration of 10 2% by weight, and (v) polysorbates at a concentration of 2 0.5% by weight.

The components are to be adapted to one another, of course, so that a sum of 100% is achieved.

Definitions Azelaic acid and its production is described in German Patent DE 28 17 133.7. Cf. Rompp, Chemie Lexikon (Lexicon of Chemistry), issued by Jiirgen FALBE and Manfred REGNITZ, 1989, 9th Edition, page 323, Thieme Verlag Stuttgart, ISBN 3-13-734609-6.

Polyacrylic acid represents an anion-active polymerizate of acrylic acid, which is only partially water-soluble. The one-percent aqueous suspension has a pH of 3 and approximately the same viscosity as water. It is only during neutralization with inorganic or organic bases that gel formation and the production of highly viscous products take place. Rudolf VOIGT and Manfred BORNSCHEIN, 1979, Lehrbuch der pharmazeutischen Technologie [Textbook of Pharmaceutical Technology], page 314, VEB Verlag Volk und Gesundheit Berlin. Cf. Rompp, Chemie Lexikon, issued by JUrgen FALBE and Manfred REGNITZ, 1992, 9th Edition, page 3508, Thieme Verlag Stuttgart, ISBN 3-13-735009-3.

"Triglyceride" is a designation for esters of the glycerine whose three hydrogen groups are esterified by carboxylic acids.
The naturally occurring fats and fatty oils are triglycerides ("neutral fats"), which generally contain various fatty acids in the same glycerine molecule. J. Am.-Oil. Chem Soc. Vol. 62, page 730, (1985); and ParfUm, Kosmet. [Perfume, Cosmet.], Vol. 58, page 353, (1977); and Rompp, Chemie Lexikon, issued by JUrgen FALBE and Manfred REGNITZ, 1990, 9th Edition, pages 1339-1342, Thieme Verlag Stuttgart, ISBN 3-13-734709-2.

Propylene glycol is described in H. P. FIEDLER: Lexikon der Hilfsstoffe [Lexicon of Adjuvants], 4th Edition, 1996, ISBN 3-87193-173 on pages 1278 to 1282.

Polysorbates are described in H. P. FIEDLER: Lexikon der Hilfsstoffe, 4th Edition, 1996, ISBN 3-87193-173 on pages 1251 to 1252.

Lecithins are obtained by extraction from biological material. A lecithin fraction from soybeans (the most common raw material) thus comprises, e.g., palmitic acid, stearic acid, palmitoleic acid, oleic acid, linoleic acid and linolenic acid.
Normally, the saturated fatty acid with the primary hydroxy group of the glycerine and the unsaturated fatty acid with the secondary hydroxy group of the glycerine are esterified.
Lecithins are components of cell membranes of all living creatures. In water, lecithins first swell up like lyophilic colloids. Later, they produce transparent, colloidal solutions.
Depending on water content, they form different textures, whereby the lamellae are formed from lipid-double layers. Liposomes are produced at higher water content. Lit.: Pardun, Die Pflanzenlecithine [The Plant Lecithins], Augsburg: Verl. fi,ir Chem. Ind. (Ziolkowsky KG) 1988. Other lecithins and their action are described in J. GAREISS et al. 1994, Parftimerie und Kosmetik [Perfumes and Cosmetics], Vol. 10/94, pages 652-659, HUthing GmbH Heidelberg.

A gel is distinguished by the following properties: it is a dimensionally stable, easily deformable, liquid and optionally gas-rich, dispersed system that consists of at least two components. Rompp, Chemie Lexikon, issued by JUrgen FALBE and Manfred REGNITZ, 1990, 9th Edition, page 1511, Thieme Verlag Stuttgart, ISBN 3-13-734709-2; and Pharm. Unserer Zeit, Vol. 8, pages 179-to 188, (1979): and Parfum., Kosmet., Vol. 58, pages 251 to 253 (1977).

Preservatives can be contained in the aqueous phase.
Preservatives include, for example, benzoic acid. Based on its antimicrobial property, benzoic acid is especially suitable as a preservative.

Properties When Used as a Medication The composition of the invention shows pharmacological action and can be used as a therapeutic active ingredient or as a medication.

Preferred is a.composition according to the invention together with at least one physiologically compatible, pharmacological adjuvant or vehicle. Pharmacological adjuvants and vehicles are described in Remington's Pharmaceutical Science, 15th Edition, Mack Publishing Company, Easton, Pennsylvania (1980).

The composition of the invention is-suitable for the treatment of various indications. Preferred is a composition of the invention as a therapeutic active ingredient for treating rosacea, presbyderma, melasma, acne and/or skin irritations.

More preferred is a composition of the invention as a therapeutic active ingredient for treating rosacea, presbyderma, melasma, acne and/or skin irritations together with at least one physiologically compatible, pharmacological adjuvant or vehicle.
The treatment comprises prophylactic and therapeutic measures.
(i) In addition, the invention provides (a) the use of the pharmaceutical composition of the invention for the production of a medication for treating rosacea, presbyderma, melasma, acne and/or skin irritations;

(8) a process for treating rosacea, presbyderma, melasma, acne and/or skin irritations, said process comprises an administration of a pharmaceutical composition according to the invention, whereby the amount suppresses the disease, and whereby the pharmaceutical composition is given to a patient who requires such a medication;

(y) a pharmaceutical composition for treating rosacea, presbyderma, melasma, acne and/or skin irritations, said treatment comprises a pharmaceutical composition of the invention and at least one pharmaceutically compatible vehicle and additive.

For these therapeutic actions, the suitable dose is different and depends on, for example, the concentration of the individual elements in the pharmaceutical composition, the host, the type of administration and the type and severity of the conditions to be treated.

In the case of topical treatment, the pharmaceutical composition of the invention can be administered in any usual way. Gel is preferred.

The pharmaceutical composition of the invention can be administered in the usual topical methods of administration with the additives and/or vehicles that are commonly used in galenical pharmaceutics according to methods that are known in the art.

Examples 1. Production of the Pharmaceutical Composition A pharmaceutical composition that contains azelaic acid has the following formulation and the following process steps:
Benzoic acid and EDTA are dissolved in usual concentrations in 60 to 70 parts of water. Then, a mixture of 1 part of mid-chain triglycerides and 1.5 parts of polysorbate 80 is to be added and homogenized while being stirred (pre-emulsion). One part of lecithin is introduced into 12 parts of propylene glycol.
The solution that is produced is stirred into the pre-emulsion and homogenized. After 1 part of polyacrylic acid is added, 15 parts of azelaic acid are introduced into the pharmaceutical composition that is produced. Then, the orientation of the gel former is carried out with the necessary amount of sodium hydroxide solution. The resulting gel has an approximately 4-times higher availability of azelaic acid in living skin layers and/or cutaneous organs.

2. Detection of Bioavailability in the Skin The percutaneous resorption of azelaic acid was examined from hydrogel formulations according to the invention in comparison to Skinoren(R) cream. The purpose of the study was to describe the bioavailability of azelaic acid in the skin, the penetration of azelaic acid through the skin and the dermal metabolism of azelaic acid. In this respect, various preparations that contain 14C-labeled azelaic acid were applied in the in vitro model of the diffusion chamber test according to Franz on the intact complete skin of hairless mice (MF1 hr/hr Ola/Hsd; supplier: Winkelmann, Germany).
An amount of 10 to 15 mg of the following compositions was applied to a skin area of 2 cm2: -A) 20% azelaic acid in a cream whose adjuvant composition corresponds to that of Skinoren(R) cream, B) 15% azelaic acid in a composition according to the invention.

The time behavior of the 14C-azelaic acid was measured in the acceptor medium (Hepes Hanks Balanced Salt Solution: HHBSS), which flows along under the skin, at two-hour intervals over a period of 24 hours. In addition, at the end of each experiment, the radioactivity on the skin surface, in the stratum corneum and in the remaining skin was determined. To study the metabolism of azelaic acid in the skin, skin extracts and selected fractions of the acceptor medium were examined using radiochromatography (HPLC
and radiometric detection).

The 14C-azelaic acid found in the skin at the end of the experiment was metabolized only to a proportion of 3 to 11%.
Therefore, the data on the radioactivity in the skin can virtually be equated to the concentration of unchanged azelaic acid.

The following table contains a summary of the results:
Cream According to Composition the Prior Art According to tbe Invention Mean SD Mean SD
Non-penetrated 79.9% 14.3% 63.6% 20.6%
azelaic acid Azelaic acid in the 0.9% 0.7% 4.0% 1.9%
stratum corneum Azelaic acid in the 3.7% 2.0% 27.3% 17.1%
remaining skin Azelaic acid in the 16.3% 6.3% 5.8% 3.3%
acceptor medium SD = standard deviation In comparison to the standard cream, considerably higher azelaic acid concentrations in the skin were achieved with the agent according to the invention.

Claims (15)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A composition comprising azelaic acid as therapeutically-active ingredient, a triacylglyceride, propylene glycol, a polysorbate, polyacrylic acid and lecithin, in an aqueous phase that comprises water and salts and wherein the composition is a hydrogel.
2. A composition according to claim 1, wherein the azelaic acid is present at a concentration of 5 to 20%, by weight.
3. A composition comprising:

(i) azelaic acid as therapeutically-active ingredient in a concentration of 5 to 20% by weight;

(ii) at least one triacylglyceride in a concentration of 0.5 to 5% by weight;

(iii) propylene glycol;

(iv) at least one polysorbate;

(v) at least one polyacrylic acid; and (vi) lecithin;

in an aqueous phase in the form of a hydrogel comprising water and salts.
4. A composition according to claim 3, wherein the following components, independently of one another, have the concentrations:

(iii) propylene glycol at a concentration of 5 to 15% by weight;
(iv) a polysorbate or polysorbates at a concentration of 0.5 to 3% by weight; and (v) a polyacrylic acid or polyacrylic acids at a concentration of 0.5 to 2% by weight.
5. A composition according to claim 4, wherein the following components, independently of one another, have the concentrations:
(ii) a triacylglyceride or triacylglycerides at a concentration of 2 ~ 1% by weight;
(iii) propylene glycol at a concentration of 10 ~ 2% by weight;
(iv) a polysorbate or polysorbates at a concentration of 2 ~ 0.5% by weight; and (v) a polyacrylic acid or polyacrylic acids at a concentration of 1 ~ 0.25% by weight.
6. A composition according to claim 4 or 5, wherein the azelaic acid is present at a concentration of 10 to 18% by weight.
7. A composition according to any one of claims 1 to 6, wherein the lecithin is soybean lecithin.
8. A composition according to any one of claims 1 to 7, wherein the lecithin is present at a concentration of up to 3% by weight.
9. A composition according to claim 8, wherein the lecithin is present at a concentration of up to 1% by weight.
10. A composition according to any one of claims 1 to 9, further comprising benzoic acid.
11. A composition according to any one of claims 1 to 10, wherein the composition further comprises an additional physiologically-compatible pharmacological adjuvant or vehicle.
12. A composition according to any one of claims 1 to 11, wherein the composition is formulated for topical administration.
13. A composition according to any one of claims 1 to 12, for use in the treatment of rosacea, presbyderma, melasma, acne or skin irritation in a patient.
14. Use of a composition as defined in any one of claims 1 to 12 for treating a condition of rosacea, presbyderma, melasma, acne or skin irritation in a patient.
15. Use of a composition as defined in any one of claims 1 to 12 for the manufacture of a medicament for treating a condition of rosacea, presbyderma, melasma, acne or skin irritation in a patient.
CA002311128A 1997-11-19 1998-11-18 Composition with azelaic acid Expired - Lifetime CA2311128C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE19753044.3 1997-11-19
DE19753044 1997-11-19
US7485098P 1998-02-12 1998-02-12
US60/074,850 1998-02-12
DE19808086.7 1998-02-20
DE19808086 1998-02-20
PCT/EP1998/007370 WO1999025332A1 (en) 1997-11-19 1998-11-18 Composition with azelaic acid

Publications (2)

Publication Number Publication Date
CA2311128A1 CA2311128A1 (en) 1999-05-27
CA2311128C true CA2311128C (en) 2008-01-29

Family

ID=27217979

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002311128A Expired - Lifetime CA2311128C (en) 1997-11-19 1998-11-18 Composition with azelaic acid

Country Status (21)

Country Link
US (1) US6534070B1 (en)
EP (1) EP1032379B1 (en)
JP (1) JP3867123B2 (en)
KR (1) KR100534511B1 (en)
AT (1) ATE210438T1 (en)
AU (1) AU743437B2 (en)
BR (1) BR9814214B1 (en)
CA (1) CA2311128C (en)
CZ (1) CZ299116B6 (en)
DE (2) DE19881737D2 (en)
DK (1) DK1032379T3 (en)
ES (1) ES2169566T3 (en)
HU (1) HU226592B1 (en)
IL (1) IL136101A (en)
IS (1) IS2257B (en)
NO (1) NO327712B1 (en)
PL (1) PL202454B1 (en)
PT (1) PT1032379E (en)
SK (1) SK284338B6 (en)
TR (1) TR200001393T2 (en)
WO (1) WO1999025332A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026982A1 (en) * 2003-06-10 2005-02-03 Soenke Johannsen Composition that consists of alkanedicarboxylic acids and a pharmaceutical active ingredient
PL1633374T3 (en) * 2003-06-10 2008-03-31 Intendis Gmbh Composition consisting of alkane dicarboxylic acids and a pharmaceutically active ingredient
DE50305909D1 (en) * 2003-10-13 2007-01-18 Salama Zoser B Pharmaceutical composition comprising oxoplatin and its salts
DE10356288B4 (en) 2003-11-28 2014-04-03 Siemens Aktiengesellschaft X-ray detector tray
CA2600054A1 (en) * 2005-03-09 2006-09-21 Combe Incorporated Stable mixed emulsions
EP1926466A2 (en) * 2005-09-19 2008-06-04 Combe Incorporated Stable emulsion systems with high salt tolerance
KR100861978B1 (en) * 2007-03-22 2008-10-07 한국콜마 주식회사 Cosmetic composition for the treatment of acne using azelaic acid and preparation method thereof
US8729108B2 (en) * 2008-06-17 2014-05-20 Christopher J Dannaker Waterborne topical compositions for the delivery of active ingredients such as azelaic acid
EP2201930A1 (en) 2008-12-23 2010-06-30 Intendis GmbH Hydrogel composition for the treatment of dermatological disorders
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
PL217786B1 (en) * 2009-05-28 2014-08-29 P P F Hasco Lek Spółka Akcyjna Gel containing azelaic acid and method for production of a gel containing azelaic acid
DE112010003355T5 (en) 2009-08-21 2012-07-12 Targeted Delivery Technologies Ltd. Vesicular formulations
DE102010021671A1 (en) 2010-05-27 2011-12-01 Intendis Gmbh Azelaic acid-containing formulation with added pigment
GB201205642D0 (en) * 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
LT3316857T (en) 2015-06-30 2021-11-25 Sequessome Technology Holdings Limited MULTI - PHASE COMPOSITIONS
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
CN116747147B (en) * 2023-04-27 2025-10-17 南京市苗本堂健康管理有限公司 Azelaic acid micro-nano crystal suspension for targeted acne removal and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3811081A1 (en) 1988-03-30 1989-10-12 Schering Ag USE OF TOPIC APPLICABLE PREPARATIONS FOR THE TREATMENT OF AGING SKIN
JP3008131B2 (en) * 1990-11-14 2000-02-14 ロレアル Nonionic amphiphilic compounds derived from glycerin, methods for their preparation, corresponding intermediate compounds and compositions containing said compounds
GB9316323D0 (en) * 1993-08-06 1993-09-22 Procter & Gamble Cosmetic compositions
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
ES2094688B1 (en) 1994-08-08 1997-08-01 Cusi Lab MANOEMULSION OF THE TYPE OF OIL IN WATER, USEFUL AS AN OPHTHALMIC VEHICLE AND PROCEDURE FOR ITS PREPARATION.
US5547989A (en) * 1994-08-19 1996-08-20 Schering-Plough Healthcare Products, Inc. Compositions for treating corns and calluses
US5618522A (en) * 1995-01-20 1997-04-08 The Procter & Gamble Company Emulsion compositions
UY24246A1 (en) 1995-06-06 1996-06-14 Neutrogena Corp TROPIC VEHICLES CONTAINING SOLUBILIZED AND STABILIZED AZELAIC ACID

Also Published As

Publication number Publication date
ATE210438T1 (en) 2001-12-15
NO20002487L (en) 2000-07-18
DK1032379T3 (en) 2002-04-02
US6534070B1 (en) 2003-03-18
BR9814214B1 (en) 2010-07-13
HU226592B1 (en) 2009-04-28
IL136101A0 (en) 2001-05-20
PL202454B1 (en) 2009-06-30
KR100534511B1 (en) 2005-12-08
HUP0004375A2 (en) 2001-08-28
AU1755199A (en) 1999-06-07
NO327712B1 (en) 2009-09-14
IS2257B (en) 2007-06-15
ES2169566T3 (en) 2002-07-01
IL136101A (en) 2005-08-31
HUP0004375A3 (en) 2006-06-28
EP1032379A1 (en) 2000-09-06
TR200001393T2 (en) 2000-10-23
JP2001522879A (en) 2001-11-20
SK7082000A3 (en) 2001-06-11
SK284338B6 (en) 2005-02-04
JP3867123B2 (en) 2007-01-10
WO1999025332A1 (en) 1999-05-27
DE19881737D2 (en) 2001-03-22
PT1032379E (en) 2002-06-28
EP1032379B1 (en) 2001-12-12
AU743437B2 (en) 2002-01-24
IS5484A (en) 2000-05-09
DE59802473D1 (en) 2002-01-24
PL340631A1 (en) 2001-02-12
BR9814214A (en) 2000-10-03
CA2311128A1 (en) 1999-05-27
CZ20001844A3 (en) 2000-10-11
KR20010032229A (en) 2001-04-16
CZ299116B6 (en) 2008-04-30
NO20002487D0 (en) 2000-05-12

Similar Documents

Publication Publication Date Title
CA2311128C (en) Composition with azelaic acid
EP1282446B1 (en) Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid
US5147859A (en) Complexes of glycerrhetinic acid with phospholipids and pharmaceutical and cosmetic compositions containing them
EP0935457B1 (en) Preparation for the transport of an active substance across barriers
EP0616801A1 (en) Process for preparing a liposome dispersion at high pressure
ES2596720B1 (en) Compositions for topical use
KR20120026050A (en) Stable pharmaceutical compositions of diclofenac
DE4021083C2 (en) Phospholipid formulations and their use for the preparation of liposomal medical and cosmetic baths
EP3283055A1 (en) Natural-substance combination containing at least one glycyrrhetinic acid and at least one guggelsterone and use thereof for cosmetic applications
EP3568123B1 (en) Introduction of hardly soluble and/or watersoluble active agents with lipid based nanoparticles/nanovesicles into a hydrophilic threedimensional network of cellulose
KR100836035B1 (en) Saturated and unsaturated lecithin-containing nanoemulsions and cosmetic compositions containing the same
WO2002083099A1 (en) Pharmaceutical formulations containing anti-inflammatory active ingredients and the use of said formulations
HK1249848A1 (en) Aqueous solutions of lipophilic substances, in particular medicinal solutions
JP4067211B2 (en) Skin preparation
MXPA00004908A (en) Composition with azelaic acid
DE69926633T2 (en) INJECTABLE MEDICINE PREORMULATIONS OF PARTRICINE DERIVATIVES
JP2005325076A (en) Skin care preparation for external use having anti-inflammatory action
TWI911987B (en) A compound composition containing tranexamic acid and tretinoin
EP1633374B1 (en) Composition consisting of alkane dicarboxylic acids and a pharmaceutically active ingredient
de Lemos Formulation, Characterization and Stability Studies of Emulsions Containing Different Vegetable Oils and Caffeine as Active Compound
El-Kattan Optimization and characterization of drug percutaneous permeation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181119